GHB

Narcolepsy Drugs Market, Size, Global Forecast 2024-2030: Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, December 29, 2023
Health, Pharmaceutical, Novartis, Teva Pharmaceuticals, Quality of life, Sodium oxybate, Food, Risk, Drug development, Takeda Pharmaceutical Company, Roche, Research, Cataplexy, FDA, Instability, Prevalence, NINDS, Incidence, Mazindol, GHB, Stimulant, EDS, NMPA, Narcolepsy, Tobacco, DSM-IV codes, Investment, Patient, Diagnosis, Organization, Somnolence, Neurological disorder, Pharmaceutical industry

The "Narcolepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Narcolepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Global Narcolepsy Drugs Market is poised for substantial growth, with a projected value of US$5.95 billion by 2030
    Several factors contribute to the expansion of the narcolepsy drugs market.
  • The Narcolepsy Drugs Market is expected to grow steadily, with a compound annual growth rate (CAGR) of 8.01% from 2023 to 2030.
  • Combined, these elements make the U.S. narcolepsy drugs market a leader in global healthcare.

Prodrugs: pills your body converts into an illicit drug can evade detection, but we don't know how big the problem is

Retrieved on: 
Monday, July 24, 2023
Psychoactive drug, Cognition, Seizure, Legislation, GHB, Misuse of Drugs Act 1971, Urine, Plasma protein binding, Enzyme, Ground substance, Human, Gastric acid, Psychoactive Substances Act 2016, Emotion, LSD, COVID, Cell, Carbon, Heroin, Prodrug, GBL, Government, Stomach, Abuse, Protein, Cocaine, Metabolism, Police, Blood, Adderall, Non-Euclidean geometry, Cannabis, Ketamine, Prohibition, Death, MDMA, Saliva, Drug, Medicinal plants, Jet fuel, Medical device, Pharmaceutical industry

Prodrugs are substances that can only cause an effect after being broken down by enzymes in the digestive system or other chemical reactions in the body.

Key Points: 
  • Prodrugs are substances that can only cause an effect after being broken down by enzymes in the digestive system or other chemical reactions in the body.
  • Most illicit drugs work by interacting with specific brain cell receptors, stimulating or blocking the release of chemicals called neurotransmitters.
  • They last for a short time before being transformed into inactive or less active chemicals, which are then eliminated from the body, usually in urine.
  • For prodrugs, however, a small part of the molecule needs to be removed or substituted before it can act on those receptors.

Hard to detect

    • A major problem with prodrugs is they are difficult to detect.
    • Police forces need reference samples to compare the drug with, or advanced equipment to discover its molecular structure.
    • It also explains why many have only appeared in police reports in the past decade.
    • For biological samples (such as blood, urine or saliva), there is another difficulty.

Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Retrieved on: 
Monday, July 3, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Seizure, Sodium chloride, Dapsone, Central nervous system, Depression, Medicine, GHB, Hypotension, Anxiety, Nelarabine, USP, Suicide, CNS, Abuse, Syncope, Mometasone, Hypoventilation, Medroxyprogesterone acetate, Coma, Confusion, Dexmedetomidine, Patient, Injection (medicine), Death, Sodium oxybate, Consciousness, Birth control, Pharmaceutical industry, Medroxyprogesterone

Dexmedetomidine hydrochloride in 0.9% sodium chloride injection, 4 mcg/mL (200 mcg/50 mL and 400 mcg/100 mL) is a generic version of Precedex® Injection.

Key Points: 
  • Dexmedetomidine hydrochloride in 0.9% sodium chloride injection, 4 mcg/mL (200 mcg/50 mL and 400 mcg/100 mL) is a generic version of Precedex® Injection.
  • For full prescribing information, see package insert located here .
  • Nelarabine injection, 250mg/50mL (5mg/mL) is a generic version of Arranon® Injection.
  • Patients must be enrolled in the XYWAV and XYREM REMS to receive Sodium Oxybate Oral Solution.

World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board

Retrieved on: 
Tuesday, May 30, 2023
IHL, Clarion, Benzodiazepine, California Institute for Regenerative Medicine, Johns Hopkins School of Medicine, California Institute of Integral Studies, Caffeine, Psychedelic drug, Johns Hopkins University, Patient, Principal, Psilocybin, Emergency medicine, GHB, Principal investigator, Research, Private practice, Certification, Terminal, Cocaine, Psychedelic therapy, The MINDS Foundation, Psychiatry, Cannabis, Addiction, MDA, DPT, NIH, PTSD, Depression, Sunstone, DSM-IV codes, LSD, Alcoholism, Advisory board, Ketamine, Johns Hopkins Center for Health Security, Behavioural sciences, Johns Hopkins, Economics, Yoga, Methamphetamine, ASX, Consciousness, Trust, CQD, Dextromethorphan, Medical director, Episode, MDMA, Pharmaceutical industry, Nursing

MELBOURNE, Australia, May 30, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’), a pharmaceutical company developing proprietary drugs which use cannabis as an ingredient for unmet medical needs, psychedelic-assisted psychotherapy protocols, and an operator of psychedelic-assisted psychotherapy clinics, is pleased to announce that three of the world’s top psychedelic therapy and science experts have joined the Advisory Board of Clarion Clinics Group.

Key Points: 
  • Three world-leading clinical psychedelics experts join Clarion Clinics Advisory Board.
  • The company is delighted to announce that, in addition to the most experienced psychedelics professionals in Australia taking key executive roles and directorships in the Clarion Clinics Group, three of the world’s most experienced and leading clinical psychedelic experts have joined its Advisory Board.
  • Andrea serves as the Medical Director of the OVID Clinics in Berlin, and is a co-founder and advisory board member of the MIND Foundation.
  • I’m grateful for their trust and support.”
    Peter Widdows, Incannex Director, said: “I’m delighted and honoured that such esteemed professionals have decided to join the Clarion Clinics team.

New Research Finds Dramatic Increase in Illegal Ketamine Seized by Authorities, Sparking Concern About Potential Dangers of Rising Recreational Use

Retrieved on: 
Wednesday, May 24, 2023
Linda, Columbia University, Seizure, Nuffield Department of Population Health, Yale University, Telehealth, Depression, University, GHB, COVID-19, Fear, NYU, Ground substance, New York University Grossman School of Medicine, Research, Heroin, Bangladesh Technical Education Board, Government, NYU Langone Health, Dissociative, Cocaine, National Institute on Drug Abuse, Patient, Risk, Population health, Ketamine, Drug, MPH, Chronic pain, Fentanyl, JAMA Psychiatry, MDMA, Dietary supplement, Pharmaceutical industry, Health, Doctor of Philosophy

"Unlike illegal ketamine years ago, most illegally obtained ketamine today is not pharmaceutical grade and is sold in powder form which may increase the risk that it contains other drugs such as fentanyl."

Key Points: 
  • "Unlike illegal ketamine years ago, most illegally obtained ketamine today is not pharmaceutical grade and is sold in powder form which may increase the risk that it contains other drugs such as fentanyl."
  • He also warns that media and medical promotion of prescription ketamine in recent years is fueling black-market use and availability.
  • NDEWS continues to monitor the use and effects of ketamine and many novel drugs to alert the public about alarming trends in a timely manner.
  • The content of this research is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Psychedelic Drugs Global Market Report 2023: Sector to Reach $5.7 Billion by 2027 at a 7.5% CAGR - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 27, 2023
Alternative Medicine, Pharmaceutical, Health, Depression, Opioid, GHB, Anxiety, Narcolepsy, Intelligence, Pfizer, Research, Psychedelic drug, Row, Ketamine, Post-traumatic stress disorder, Addiction, Ecosystem, Environment, Pharmaceutical industry, Drug, Fine chemical

The global market for psychedelic drugs reached $3.7 billion in 2021.

Key Points: 
  • The global market for psychedelic drugs reached $3.7 billion in 2021.
  • This market is projected to grow at a compound annual growth rate (CAGR) of 7.5% and reach $5.7 billion by the end of 2027.
  • Growing scientific support for the benefits of psychedelic drugs, regulatory advancements supporting the development of psychedelic drugs, and increasing patient and physician acceptance of these drugs are key growth drivers of the market.
  • In 2021 the North American market for psychedelic drugs was valued at $1.5 billion, representing approximately 41.5% of the global market.

Alcohol Use Disorder Market to Witness Positive Growth at a CAGR of 8.8% by 2032 | DelveInsight

Retrieved on: 
Wednesday, September 28, 2022
Memantine, New, Social stigma, GHB, Perspiration, Compliance, ASP, Topiramate, Lists of diseases, Patient, Disulfiram, United Kingdom, Benzodiazepine, Astellas Pharma, National Institute, AUD, Psychiatric and mental health nursing, Prevalence, GABAB, Knowledge, Biomarker, Growth, Acamprosate, Alcoholism, Attention, Otsuka Pharmaceutical, Diagnostic and Statistical Manual of Mental Disorders, Drinking, ALKS, Health care, SMO, Gabapentin, Seizure, Corcept Therapeutics, Diagnosis, Hope, Population, Baclofen, Sodium oxybate, DSM, CORT, DSM-IV, LAS, VIVITROL, Mood Swings, National Institute on Alcohol Abuse and Alcoholism, Aripiprazole, Therapy, ALKS 3831, US FDA, DSM-V, Varenicline, Novo Nordisk, Pharmaceutical industry, Lithium, Alkermes, Ondansetron

LAS VEGAS, Sept. 28, 2022 /PRNewswire/ --DelveInsight's Alcohol Use Disorder Market Insights report includes a comprehensive understanding of current treatment practices, alcohol use disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Points: 
  • Leading alcohol use disordercompanies such as Alkermes, Lundbeck, Otsuka Pharmaceuticals, Adial Pharmaceuticals, MediciNova, Corcept Therapeutics, Astellas Pharma, Bioprojet, and others are developing novel alcohol use disorder drugs that can be available in the alcohol use disorder market in the upcoming years.
  • DelveInsight estimates that there were approximately 25 million 12-month diagnosed prevalent cases of alcohol use disorder in the 7MM in 2021.
  • TOPAMAX (topiramate) is even recommended for alcohol use disorder treatment by the National Institute on Alcohol Abuse and Alcoholism.
  • Moreover, because of the change in alcohol use disorder diagnostic criteria from DSM-IV to DSM-V, country-specific epidemiologic data on diagnosis, severity, and treatment are scarce and thus limiting the alcohol use disorder market growth.

Psychedelic Drugs Global Market Report 2022: Featuring Key Players Johnson & Johnson, Pfizer, Hikma Pharmaceuticals & Others - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022
Mental Health, Arts, Museums, Entertainment, Other Health, Alternative Medicine, Managed Care, Music, General Health, Pharmaceutical, Health, Opioid, Depression, Johnson & Johnson, Hallucinogen, Lysergic acid diethylamide, Salvia, National Alliance on Mental Illness, Growth, Brain, Behavior, Plant, Perception, Narcolepsy, Patient, Lists of diseases, National Alliance, GHB, LSD, Panic, Mental disorder, Post-traumatic stress disorder, Esketamine, Thought, Pharmacy, PTSD, Gamma-Hydroxybutyric acid, Mental, NAMI, Organization, Pharmaceutical industry, Medicine, Ketamine, Phencyclidine

The "Psychedelic Drugs Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Psychedelic Drugs Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • These drugs are a group of substances that usually alter and enhance perception, thinking processes, energy levels, and promote mental experiences.
  • Major companies operating in the psychedelic drug market are introducing nasal-spray drugs for major depressive disorders to sustain their position in the market.
  • For instance, in March 2019, Johnson & Johnson, a US-based company that manufactures psychedelic drugs and pharma medicines, launched a new depression spray named Spravato.

MIMEDX Comments on Prescience Point’s False and Misleading Statements

Retrieved on: 
Monday, May 9, 2022
M&A, Culture, Board of directors, GBL, Arthur Andersen, Solution, Stanford University, Cancer Prevention and Research Institute of Texas, IQVIA, Annual general meeting, Risk, Chairperson, THC, RISK, NASDAQ, Control, Company, NYSE, Research institute, Investment, Novin, Industry, Pressure, Owens & Minor, Intention, Statement, ALL, Telephone, GHB, Gamma-Hydroxybutyric acid, LLP, Sale, Goal, Motivation, Growth, Ownership, Internet, Cancer prevention, Board, COVID-19, OMI, GLOBE, Review, Shareholder, Tenet Healthcare, Ethics, History, Science, AUM, Security (finance), Management, Risk management, Theranos, Medicine

MARIETTA, Ga., May 09, 2022 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today commented on Prescience Point Capital Management’s (“Prescience Point”) highly misleading press release on May 6, 2022. MIMEDX urges shareholders to vote “FOR” the Company’s highly qualified and independent directors – Dr. Phyllis Gardner and James L. Bierman – on the WHITE proxy card.

Key Points: 
  • A companys integrity and credibility stem from exemplary leadership, and MIMEDX does not compromise on its core values and commitments.
  • Both are highly respected in the life sciences industry and have made significant contributions to our successful turnaround, positioning MIMEDX for substantial shareholder value creation.
  • Mr. Asbahis commentary only reinforces the Boards belief that Prescience Points interests are short-term and not aligned with those of all shareholders.
  • While Prescience Point attempts to distract shareholders with misleading facts and statements, their public comments betray their true motivation Mr. Asbahi and Prescience Point explicitly stated their interest in a sale of AMNIOFIX or the entire business later this year.

Red Carpet Gala kick offs launch of revolutionary new anti-rape tool

Retrieved on: 
Wednesday, January 19, 2022
People, RAINN, GHB, Ketamine, Rape, Color, Safety net, Sexual assault, Abduction, Ridesharing company, Sex industry

"People can rest easier knowing their drink is going to notify them if someone makes an attempt to violate their rights."

Key Points: 
  • "People can rest easier knowing their drink is going to notify them if someone makes an attempt to violate their rights."
  • The product, which has been approved by John Hopkins , will be demoed at the gala.
  • Tickets for the event - a red carpet event hosted at the luxurious Los Angeles Mayfair - can be purchased at http://www.experiencesafetynet.com .
  • "Rapists and human traffickers will think twice if there's a readily available product that will catch them in the act."